Neurotrophins are critically involved in regulating normal neural development and plasticity. Brain-derived neurotrophic factor (BDNF), a neurotrophin that acts by binding to the tropomyosin receptor kinase B (TrkB) receptor, has also been implicated in the progression of several types of cancer. However, its role in medulloblastoma (MB), the 
Introduction
Medulloblastomas (MBs) are highly aggressive and heterogeneous brain tumors of the cerebellum that account for about 20% of pediatric brain cancers [1, 2] . Integrative genomic and epigenomic studies on MB biology classify this disease into four clinically relevant consensus subgroups: wingless (Wnt), Sonic hedgehog (Shh), group 3 and group 4 [3, 4] . The 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System recently acknowledged the molecular subgroups in the classification of MBs, providing clinical utility for the improvement of MB diagnosis [5] .
More recent advancements in deep transcriptional and methylation profiling of 763 primary MB samples revealed new subtypes within each of the four subgroups and further classified MB into 12 subtypes: two Wnt, four Shh, three group 3, and three group 4 subgroups [6] . Current treatment is based in risk stratification and despite significant advances in surgery, radiotherapy, and drug therapy, effective treatment to MB remains a challenge [2, 7] . Because irradiating the central nervous system (CNS) can be harmful to the developing brain, radiation therapy is typically avoided in children under the age of three, but this can compromise disease control and survival. Consequently, there is a need for new treatments that can be tolerated in the younger population to treat therapyresistant disease as well as to decrease potential side effects [2, 8] .
Targeting oncogenic fusions and dysregulated signal transduction pathways is an approach that can potentially improve the outcome of pediatric tumors therapy.
Neurotrophins (NT) are a group of growth factors that stimulates cell survival pathways through the activation of the tropomyosin receptor kinase (Trk) receptors. The Trk family includes TrkA, TrkB and TrkC, which are encoded by NTRK1, NTRK2 and NTRK3 5 genes, respectively. TrkA is the high-affinity receptor for nerve growth factor (NGF), whereas TrkB has high affinity for brain-derived neurotrophic factor (BDNF) and NT-4.
NT-3 can bind to all Trk receptors but has highest affinity for TrkC and is the sole ligand of this receptor [9, 10] . NTs were initially characterized for their roles in regulating development and plasticity in the CNS [10] . However, it is now clear that deregulation of NT signaling is involved in the pathogenesis and progression of several tumor types [11] .
Gene fusions involving NTRK genes that lead to transcription of chimeric Trk proteins with constitutively activate or overexpressed kinase function conferring oncogenic potential have become increasingly important targets for cancer therapy [12, 13] .
Expression of NTs and Trks has been reported in MB tumor samples from patients [14] , and activation of different Trk receptors can influence MB cell function [15] .
Stimulation of TrkA by NGF and TrkC by NT-3 typically increases cell death and differentiation [16] [17] [18] , and higher TrkC expression has been associated with a favourable outcome and predictor of survival of MB patients [19, 20] . Despite substantial knowledge about TrkA and TrkC receptors in MB, the role of BDNF/TrkB in MB cells remains poorly understood [21] . Previous reports showed that BDNF or TrkB inhibition can display either pro-or antitumoral effects in these tumors [22] [23] [24] . Given that BDNF/TrkB pathway is implicated in the pathogenesis and prognosis of a wide variety of malignancies, including neuroblastoma, glioblastoma, head and neck, breast, lung, and pancreas tumors as well as leukemia, being associated with promotion of proliferation, migration, resistance to anoikis and resistance to chemotherapy [25] [26] [27] [28] , here we investigated the potential role of TrkB inhibition in experimental MB.
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Materials and Methods
Cell Culture
Human MB cell lines UW228 and D283 were obtained from the American Type Culture Collection (ATCC, Rockville, USA). The D283 cell line was cultured in Dulbecco's modified Eagle's medium (DMEM low glucose, Gibco, Grand Island, USA) while 
Ki67 Proliferation Assay
The Muse Ki67 Proliferation kit (Merck, Princeton, USA) was used to detect proliferating 
Apoptosis Assay
The Annexin V-FITC apoptosis detection kit (BD Biosciences, San Diego, USA) was used to detect apoptosis and cell death, respectively. MB cells were plated at 15 X 10 Primers are listed in Table 1 .
______________________________________________________________________ Table 1 following manufacturer's instructions. All slides were counterstained with hematoxylin, dehydrated and permanently mounted using standard procedures. Quantitative evaluation was made using IHC profiler plugin in the software image J [29] .
Mice and In Vivo Experiments
In vivo studies were performed in accordance with procedures approved by the Brazilian is the smallest measurement and the length is the longest measurement.
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Statistical Analysis
All statistical analyses were performed using GraphPad Prism software version 6.0. Data were represented as means ± standard error of mean (SEM). For comparison between two data sets, a two-tailed unpaired Mann-Whitney test was used. For analysis of three or more sets of data, ANOVA test followed by Bonferroni multiple comparison test was used. P < 0.05 was considered significant. Statistical significance is indicated in the figures as follows: *P≤0.05, **P<0.01, ***P<0.001, ****P<0.0001.
Results
Selective TrkB Inhibition Suppresses Cell Viability and Proliferation of MB Cells
To evaluate the effects of TrkB inhibition on MB cell viability, we exposed the cells to varying concentration of ANA-12 (5, 10, 20 or 30 µM) for different time periods (24, 48 or 72 h). A dose-dependent reduction of cell viability was observed in both cell lines, and increasing effects were observed with longer exposure ANA-12 (Fig. 1A) . Fifty percent inhibition of growth (IC50) was calculated for ANA-12 considering different exposure times, ranging from 23.99 to 17.42 µM in UW228 cells and 24.83 to 14.74 in D283 cells (Fig. 1B) . Moreover, changes in cell viability were accompanied by alterations in cell morphology characteristic of cell death features in both cell lines, and differentiation in UW228 cells (Fig. 1C) . 14 We next assessed cell proliferation using the Ki67 marker in cells exposed to ANA-12 for 24 h. Exposure to ANA-12 for 24 h resulted in a significant decrease in the percentage of cells positive for Ki67 (Fig. 1D) . Expression of BDNF and TrkB in MB cells was confirmed by PCR analysis (Fig. 1E) . of UW228 cells ( Fig. 2A, 2C ) and 28.78% for D283 cells (Fig. 2B, 2D (Fig. 3A, 3B , left panels). In D283 cells, ANA-12 at 20 µM or 30 µM was effective in reducing phospho-ERK (6.16% and 4.16%, respectively) when compared with control cells (16.94%) (Fig. 3A, 3B , right panels). There was also increases in negative cells, and no differences were observed for AKT or dual-pathway activation.
We 
TrkB Inhibition Differentially Modulates p21 Gene Expression in MB Cells
The cyclin-dependent kinase (CDK) inhibitor p21 is a well-known tumor suppressor that promotes cell cycle inhibition, transcriptional regulation, and modulation of apoptosis. In order to access the status of p21 expression after TrkB inhibition, we treated MB cells with ANA-12 for 6 or 24 h and then performed RT-qPCR and Western blot analyses.
TrkB inhibition led to increases in both mRNA expression and protein levels of p21 in UW228 cells in a dose-dependent manner. In addition, we observed 3 a 10.8-fold change increase of p21 mRNA expression in UW228 cells after 6 and 24 h of ANA-12 respectively (Fig. 4A, left panel) . UW228 cells exposed to 20 and 30 µM of ANA-12 for 6 h showed approximately 1.97 and 2.49-fold change increases in the protein levels of p21 (Fig. 4B, 4C , left panel).
Interestingly, opposite effects of TrkB inhibition on p21 expression were found in in D283 cells. Significant 2 to 3.3-fold decreases in p21 mRNA levels were observed in D283 cells treated with ANA-12 for 6 and 24 h respectively (Fig. 4A, right panel) . We also detected a 2.5-fold change decrease in p21 protein content in D283 cells exposed to ANA-12 for 24 h (Fig. 4B, 4C, right panel) . These results indicate differential responses of p21 expression to TrkB inhibition in different cell lines.
______________________________________________________________________
Fig. 4 should be inserted here Inhibiting TrkB Induces Morphological Changes and Alters the Expression of Differentiation and Pluripotency Markers
We went on to investigate whether morphological changes observed after ANA-12 treatment would be associated with changes in differentiation in MB cells. We observed neurite-like extensions after 24 h of ANA-12 treatment, particularly in UW228 cells (Fig.   5A , left panel) whereas D283 cells showed predominantly morphologic features associated with cell death (Fig. 5A, right panel) . Next, we performed flow cytometry analysis to evaluate the forward and side scatter characteristics, particularly the SSC-A parameter that indicates cell granularity or internal complexity. We observed an increase in cell complexity and granularity in UW228 cells treated with ANA-12 at 30 µM for 24 h (Fig. 4B, 4C) . Moreover, we measured the expression level of the neural differentiation marker β-III Tubulin (TUBB3) and the neural stem/progenitor cell marker Nestin. We found that the transcriptional expression level of Nestin was decreased in dose-dependent manner in both MB cell lines (Fig. 5D) . We also observed an 1.8-fold change increase in TUBB3 mRNA levels in UW228 cells (Fig. 5E) , however, there were no differences in the protein content of TUBB3 (Fig. 5F, 5G ). These findings suggest that UW228 cells, classified SHH MB subtype, display features of cell differentiation after TrkB inhibition, and both cell lines showed reductions of the pluripotency marker Nestin. and an average reduction in tumor volume of 35%, whereas growth continued at a high rate in control animals (Fig. 6B) . Ex-vivo tumor analysis showed an apparent reduction in tumor volume and weight, however these differences did not reach statistical significance (Fig. 6D, 6E) . Importantly, the treatment protocol used did not induce overt toxicity and there were no significant changes in animal weights over the study period (Fig. 6H) . We analysed the protein content of TrkB and phospho-TrkB in tumor samples and found reduced levels of phospho-TrkB in tumors from mice treated with ANA-12
( Fig. 6F, 6G ). Ki67 IHC staining was used to investigate the extent of proliferation in the tumors. Tumors from mice receiving ANA-12 showed a reduction of approximately 20%
in Ki67-positive tumor cells (Fig. 6F, 6G) . Finally, we verified whether ANA-12 would affect p53 expression. There was no difference in p53 staining between ANA-12-treated and control groups (Fig. 6F, 6G) . These results indicate that TrkB inhibition results in significant in vivo antitumoral activity in MB xenografts. We found that MB cells treated with ANA-12 showed a decrease in the activation of ERK signaling pathway as measured by phospho-ERK. The ERK/MAPK cascade mediates the stimulatory effects of TrkB activation on proliferation [9, 28] , and aberrant ERK signaling activation promotes proliferative stimuli in Shh and Group 4 MB [37] .
______________________________________________________________________
ANA-12 is able to reduce ERK activation induced by BDNF in astrocytes [38] and 20 prevent ERK activation in neurons [39] . These findings are consistent with the possibility that blocking TrkB activity suppresses ERK-mediated growth and survival actions in MB.
STAT3 mRNA levels were increased by treatment with ANA-12, whereas phosphor-AKT levels remained unchanged. STAT3 plays an important role as an intermediate molecule linked to TrkB and AKT activation [26] . MB tumors commonly present deregulation and aberrant expression of AKT and STAT3 and the activation of these pathways are associated with enhanced cellular survival, migration, angiogenesis and resistance to chemotherapeutic agents [40, 41] . MB brain tumor-initiating cells expressing CD133 drive recurrence mediated by STAT3 activation [42] . Thus, the upregulation in STAT3 after anticancer treatment with a TrkB inhibitor suggested by our findings could indicate a compensatory response to counteract the inhibitory effects. In fact, inhibition of receptor tyrosine kinases including the epidermal growth factor receptor (EGFR) and HER2 in experimental cancer models can trigger feedback activation of STAT3 as a possible mechanism of resistance to targeted therapies [43] . However, other studies indicate a dual role of STAT3, where it can act as a tumor suppressor. For instance, endogenous STAT3 activation or expression of a constitutively active form of STAT3 inhibit glioblastoma cell proliferation and invasiveness [44, 45] . Thus, the increase in STAT3 expression we observed in ANA-12-treated cells may contribute to the antiproliferative effect of TrkB inhibition.
Inhibiting TrkB resulted in differential modulatory effects on p21 expression in the two MB cell lines used, where UW228 cells treated with ANA-12 showed an increase in p21 transcriptional expression whereas a decrease was found in D283 cells. It is possible that the increased expression of p21 in UW228 cells is associated with growth arrest, whereas decreased expression of p21 in D283 cells might be related to apoptosis.
In addition, UW228 cells are TP53 mutated while D283 cells display TP53 expression 21 [36] . p21 displays a complex pattern of actions in regulating the cell cycle and interacting with other signaling components, and its role and expression may be different depending on p53 expression [46] .
TrkB plays a role in cell differentiation during normal CNS development. We found that UW228 cells exposed to ANA-12 showed increased cellular complexity.
Consistently with the observed morphological alterations, UW228 cells showed a small increase in mRNA levels of TUBB3 after TrkB inhibition. Upregulation of TUBB3 was previously associated with differentiation in MB cells [47] . Moreover, a decreased expression of Nestin, a marker of stemness, was detected in both MB cells treated with ANA-12. Nestin is commonly used as a marker for neural stem cell and cancer stem cell populations [48] , and its expression increases progressively during MB development [49] .
Nestin cooperates with the Shh pathway to drive tumor growth and Nestin suppression inhibits cell proliferation and promotes differentiation in MB [50] . Thus, our findings provide early evidence that TrkB might be a target to induce differentiation in MB, particularly in Shh tumors, a possibility that should be further explored by future studies.
A recent study used ANA-12 as an experimental treatment for oral squamous carcinoma in vivo and found reduction of tumor growth in a pattern consistent with our results in MB [32] . Other TrkB inhibitors has also been shown to efficiently reduce the growth of neuroblastoma in mouse models [51, 52] . Our final series of experiments provides the first evidence that TrkB inhibition slows MB growth in vivo. Together, our results support the view that specific inhibition of TrkB can be effective as a therapy for MB, likely through mechanisms involving modulation of apoptosis and cell differentiation.
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